Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Muehlbacher

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Handbook of Experimental Pharmacology|April 13, 2013
Functional inhibitors of acid sphingomyelinase (FIASMAs)Johannes Kornhuber, Philipp Tripal, Erich Gulbins, et al.
Chemmedchem|September 5, 2012
Identification of drugs inducing phospholipidosis by novel in vitro dataMarkus Muehlbacher, Philipp Tripal, Florian Roas, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|May 26, 2016
Drug-induced phospholipidosis caused by combinations of common drugs in vitroMareike Glock, Markus Muehlbacher, Henoch Hurtig, et al.
Journal of Computer-Aided Molecular Design|November 24, 2011
Qualitative prediction of blood-brain barrier permeability on a large and refined datasetMarkus Muehlbacher, Gudrun M Spitzer, Klaus R Liedl, et al.
Journal of Chemical Information and Modeling|August 17, 2011
Conformation-dependent QSPR models: logPOWMarkus Muehlbacher, Ahmed El Kerdawy, Christian Kramer, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|May 27, 2010
Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applicationsJohannes Kornhuber, Philipp Tripal, Martin Reichel, et al.
Plos One|December 11, 2012
Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validationLaura Guasch, Esther Sala, Anna Castell-Auví, et al.
Plos One|September 13, 2011
Identification of novel functional inhibitors of acid sphingomyelinaseJohannes Kornhuber, Markus Muehlbacher, Stefan Trapp, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Handbook of Experimental Pharmacology|April 13, 2013
Functional inhibitors of acid sphingomyelinase (FIASMAs)Johannes Kornhuber, Philipp Tripal, Erich Gulbins, et al.
Chemmedchem|September 5, 2012
Identification of drugs inducing phospholipidosis by novel in vitro dataMarkus Muehlbacher, Philipp Tripal, Florian Roas, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|May 26, 2016
Drug-induced phospholipidosis caused by combinations of common drugs in vitroMareike Glock, Markus Muehlbacher, Henoch Hurtig, et al.
Journal of Computer-Aided Molecular Design|November 24, 2011
Qualitative prediction of blood-brain barrier permeability on a large and refined datasetMarkus Muehlbacher, Gudrun M Spitzer, Klaus R Liedl, et al.
Journal of Chemical Information and Modeling|August 17, 2011
Conformation-dependent QSPR models: logPOWMarkus Muehlbacher, Ahmed El Kerdawy, Christian Kramer, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|May 27, 2010
Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applicationsJohannes Kornhuber, Philipp Tripal, Martin Reichel, et al.
Plos One|December 11, 2012
Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validationLaura Guasch, Esther Sala, Anna Castell-Auví, et al.
Plos One|September 13, 2011
Identification of novel functional inhibitors of acid sphingomyelinaseJohannes Kornhuber, Markus Muehlbacher, Stefan Trapp, et al.
Pageof 1